Biosimilars : design and analysis of follow-on biologics / / Shein-Chung Chow.
"Biologic drug products are therapeutic moieties that are manufactured using a living system or organism. These are important life-saving drug products for patients with unmet medical needs. They also comprise a growing segment in the pharmaceutical industry. In 2007, for instance, worldwide sa...
Saved in:
| : | |
|---|---|
| TeilnehmendeR: | |
| Year of Publication: | 2014 |
| Language: | English |
| Series: | Chapman & Hall/CRC biostatistics series ;
60 |
| Online Access: | |
| Physical Description: | xix, 410 p. :; ill. |
| Notes: | "A Chapman & Hall book." |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 02102nam a2200433 a 4500 | ||
|---|---|---|---|
| 001 | 5001316405 | ||
| 003 | MiAaPQ | ||
| 005 | 20200520144314.0 | ||
| 006 | m o d | | ||
| 007 | cr cn||||||||| | ||
| 008 | 130405s2014 fluad sb 000 0 eng d | ||
| 010 | |z 2013012926 | ||
| 020 | |z 9781466579699 (hardback) | ||
| 020 | |z 9781466579705 (e-book) | ||
| 035 | |a (MiAaPQ)5001316405 | ||
| 035 | |a (Au-PeEL)EBL1316405 | ||
| 035 | |a (CaPaEBR)ebr10733726 | ||
| 035 | |a (CaONFJC)MIL518837 | ||
| 035 | |a (OCoLC)854975436 | ||
| 040 | |a MiAaPQ |c MiAaPQ |d MiAaPQ | ||
| 050 | 4 | |a RS380 |b .C45 2014 | |
| 082 | 0 | 4 | |a 615.1/9 |2 23 |
| 100 | 1 | |a Chow, Shein-Chung, |d 1955- | |
| 245 | 1 | 0 | |a Biosimilars |h [electronic resource] : |b design and analysis of follow-on biologics / |c Shein-Chung Chow. |
| 260 | |a Boca Raton : |b Taylor & Francis, |c 2014. | ||
| 300 | |a xix, 410 p. : |b ill. | ||
| 490 | 0 | |a Chapman & Hall/CRC biostatistics series ; |v 60 | |
| 500 | |a "A Chapman & Hall book." | ||
| 504 | |a Includes bibliographical references. | ||
| 520 | |a "Biologic drug products are therapeutic moieties that are manufactured using a living system or organism. These are important life-saving drug products for patients with unmet medical needs. They also comprise a growing segment in the pharmaceutical industry. In 2007, for instance, worldwide sales of biological products reached $94 billion US dollars, accounting for about 15% of the pharmaceutical industry's gross revenue. Meanwhile, many biological products face losing their patents in the next decade"-- |c Provided by publisher. | ||
| 533 | |a Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries. | ||
| 650 | 0 | |a Pharmaceutical biotechnology. | |
| 650 | 0 | |a Pharmaceutical biotechnology industry. | |
| 650 | 0 | |a Drugs |x Generic substitution. | |
| 650 | 0 | |a Pharmaceutical policy. | |
| 650 | 0 | |a Biological products. | |
| 655 | 4 | |a Electronic books. | |
| 710 | 2 | |a ProQuest (Firm) | |
| 856 | 4 | 0 | |u https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=1316405 |z Click to View |